Background and aims The effect of multidrug resistance transporter gene 1 (MDR1) on the
bioavailability and kinetics of several substrates has not yet been fully elucidated. We …

Objectives To evaluate the influence of CYP2C19* 2/* 3 and MDR1 C3435T polymorphisms
on the pharmacokinetics of lansoprazole (LPZ) in healthy Chinese subjects. Methods All 24 …

Considering that the genotypes of CYP2C19 and MDR1 C3435T are two major factors
attributed to the inter-individual pharmacokinetic variability of lansoprazole (LSZ), the aim of …

Objective: We investigated whether interindividual differences in the pharmacokinetic
disposition of lansoprazole are attributed to the genetic polymorphism of CYP2C19 which …

ABSTRACT AIM: To study the kinetic characteristics of lansoprazole in healthy Chinese
subjects in relation to CYP2C19 genotype status for the individualized dose regimen of …

The aim of the study was to determine the pharmacokinetics of lansoprazole and its main
metabolites (5′-hydroxy lansoprazole and lansoprazole sulphone) after administration of …

Objective The purpose of this study was to elucidate the pharmacokinetics of each
enantiomer of lansoprazole and 5-hydroxylansoprazole in three different CYP2C19 …

Aims Lansoprazole is a substrate of CYP2C19 and CYP3A. The aim of this study was to
compare the inhibitory effects of clarithromycin, an inhibitor of CYP3A on the metabolism of …

Context: Lansoprazole is a gastric proton-pump inhibitor and has been demonstrated to be
effective in the treatment of various peptic diseases. The effects of CYP2C19 activity on the …

Objective To evaluate the enantioselective disposition of lansoprazole in relation to the
genetic polymorphism of CYP2C19. Methods A single oral dose of racemic lansoprazole (30 …